Introduction/Background The suitability of the Sedlis criteria for managing adjuvant treatment in cervical cancer patients remains debatable. The aim of this study is to identify predictors of recurrence of early-stage cervical cancer patients surgically treated who did not undergo neoadjuvant or adjuvant treatment.

Methodology FIGO 2018 Stage I cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy at the European Institute of Oncology, Milan from January 2010 to December 2021 were retrospectively identified. Patients with positive margins, those who received neoadjuvant or adjuvant treatment, and those with less than 12 months of follow-up were excluded. Associations between clinicopathological characteristics and recurrence were analyzed through univariate and multivariate statistical analysis.

Results A total of 297 patients meeting the inclusion criteria were included, of which 139(46,8%) were squamous carcinomas, 136(45,8%) adenocarcinomas and 22(7,4%) adenosquamous. Among them, 184(62%) underwent robotic-assisted surgery and 113(28%) open abdominal surgery. In total, 26(8,8%) recurrences were observed, with a median time of recurrence of 21,1 months (IQR 10,8–30,7). Among those not experiencing a recurrence, the median time of follow-up was 75,8 months (IQR 42,3–99,9). At univariate analysis, previous conization (p=0,002), stage (p<0,001), and grade (p=0,048) were associated with recurrence. At the multivariate analysis, stage IB3 vs. IB1 (RR=8,87) and grade 3 vs. 2(RR= 2,26) were independent predictors of recurrence.

Conclusion According to our results, grade and stage were identified as independent predictors of recurrence for early-stage cervical cancer treated with radical hysterectomy that did not receive adjuvant treatment.

Further studies are needed to validate these findings to devise more tailored adjuvant treatment strategies.

Disclosures No